title: Improvement of some schizophrenic deficit symptoms with low doses of amisulpride.
abstract: OBJECTIVE
  The authors assessed the effects on primary negative symptoms of low doses of amisulpride, a substituted benzamide neuroleptic with high affinity for D2 and D3 dopamine receptors.
  
  
  METHODS
  Young, drug-free schizophrenic patients with pure negative symptoms participated in a 6-week double-blind trial of placebo (N = 10) or low-dose amisulpride (N = 10). They were assessed with the Scale for the Assessment of Negative Symptoms.
  
  
  RESULTS
  Amisulpride significantly improved negative symptoms. Improvement in avolition, attentional impairment, and retardation was significantly greater with amisulpride than with placebo.
  
  
  CONCLUSIONS
  These findings suggest that some primary negative symptoms may be directly affected by low doses of benzamide neuroleptics.
authors: Department of Child and Adolescent Psychiatry, Hôpital de la Salpêtrière, Paris, France.
authors: M L
authors: ML
authors: Paillère-Martinot
authors: Y
authors: Y
authors: Lecrubier
authors: J L
authors: JL
authors: Martinot
authors: F
authors: F
authors: Aubin
mesh_terms: D000328:Adult; D000077582:Amisulpride; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D013469:Sulpiride / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D010919:Placebos; D011619:Psychotropic Drugs; D013469:Sulpiride; D000077582:Amisulpride